Managing Symptoms and Supportive Care in FFI
At a Glance
Fatal familial insomnia has no approved treatment that stops the disease, so care focuses on comfort and symptom relief. A neurologist and palliative care team can guide medication safety, breathing concerns, electrolyte monitoring, advance planning, and caregiver support.
Because Fatal Familial Insomnia (FFI) involves the physical destruction of the brain’s “sleep-wake switch” in the thalamus, it cannot be treated like a standard sleep disorder [1][2]. While there is currently no cure or treatment that stops the disease, care focuses on neuropalliative management—a specialized approach that prioritizes comfort, symptom relief, and quality of life for both the patient and the caregiver [3][4].
Navigating Sleep Medications
In a healthy brain, sleep is an active process. In FFI, the “toxic” prion proteins damage the thalamus so severely that the brain loses the physical ability to generate deep, restorative sleep (slow-wave sleep) [1].
Because of this structural damage, traditional medications often do not work as expected [2]:
- Benzodiazepines: Drugs like alprazolam or clonazepam may not restore normal restorative sleep in FFI patients [5][6]. However, they should not be abruptly stopped without medical guidance.
- The Goal Shift: Rather than trying to force normal sleep architecture, clinicians may selectively use medications to reduce anxiety, hallucinations, myoclonus, or distress [7].
- Caution: Benzodiazepines, antidepressants, and other sedatives must be individualized by a neurologist, as they carry significant risks, such as worsening falls, delirium, swallowing issues, and respiratory suppression [5][6].
Managing Complex Symptoms
As the disease progresses, FFI affects the entire body’s “autopilot” (autonomic) systems. Managing these physical symptoms is a core part of supportive care.
Breathing and Stridor
Many patients develop stridor—a high-pitched, strained sound indicating potential upper-airway obstruction [8][9].
- Prompt Assessment: Any new or worsening stridor or respiratory distress needs prompt clinical assessment; it is an urgent upper-airway problem and should not be assumed to be a routine issue for a home CPAP trial.
- CPAP/BiPAP: A Continuous Positive Airway Pressure (CPAP) machine may help if a specialist determines there is an obstructive component, but it does not treat central sleep apnea and can sometimes be burdensome [8][10].
Intractable Sweating and Electrolytes
Profuse, “intractable” sweating (hyperhidrosis) is a hallmark of the autonomic overactivity in FFI [11].
- Hyponatremia: Excessive sweating can lead to dangerously low salt levels in the blood (hyponatremia) or dehydration, which can cause further confusion or seizures [12].
- Management: Fluid or salt replacement and laboratory monitoring must be clinician-directed. Do not start salt or fluid replacement independently, as drinking large amounts of plain water can worsen hyponatremia [12].
Central Fever and Heart Rate
The brain’s thermostat and heart-rate controllers often malfunction, leading to high fevers and a racing heart (tachycardia) [13][7]. Crucially, high fever must not be assumed to be “central” until infection and other urgent causes have been assessed. Care involves keeping the environment cool and occasionally using medications to gently lower the heart rate if it is causing distress [11].
The Status of Experimental Treatments
You may hear about various drugs being studied for FFI, but it is important to understand that there is no approved disease-modifying treatment.
- Doxycycline: This antibiotic has been studied in symptomatic prion disease, but it has not established a disease-modifying benefit and is not a proven preventative treatment [14][15].
- Antisense Oligonucleotides (ASOs) and PrP-siRNA: This is a cutting-edge area of research aimed at lowering the production of the prion protein [16][17].
- Symptom-Focused Trials: Some studies look at specialized medications for symptom control [NCT05124392]. Trial participation involves burdens and is not assured; checking a current national trial registry (like clinicaltrials.gov) or consulting a named specialist center is necessary to find active, recruiting studies.
Creating a Palliative Care Plan
Because FFI progresses rapidly, the most important “treatment” is a proactive care plan [3].
- Early Palliative Involvement: Connecting with a palliative care team early—even at diagnosis—allows you to discuss goals of care alongside any active medical management [7].
- Hospice Care: Hospice is distinct from palliative care; eligibility depends on prognosis, local rules, and the patient’s goals. Discuss hospice with your team when eligible and consistent with the patient’s wishes [18].
- Advance Directives: Have clear, shared conversations about interventions like feeding tubes or ventilators. These decisions should consider reversible complications, the expected burdens, benefits, and the patient’s documented goals, rather than assuming they are always futile [3].
- Caregiver Support: The 24-hour nature of FFI care can lead to extreme caregiver burnout. Respite care and home nursing support should be integrated to sustain the caregiver [19].
Common questions in this guide
Why don’t sleeping pills reliably restore sleep in fatal familial insomnia?
What should we do if someone with FFI develops stridor or breathing trouble?
Can severe sweating in FFI cause low sodium?
How are fever and a fast heart rate managed in fatal familial insomnia?
Is there a cure or proven experimental treatment for fatal familial insomnia?
When should palliative or hospice care be considered for FFI?
How can caregivers cope with the demands of 24-hour FFI care?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given that traditional sedatives often fail in FFI, what are our best options for managing the anxiety and distress associated with the lack of sleep?
- 2.If my loved one develops stridor or heavy snoring, can we trial CPAP to see if it improves their comfort?
- 3.How often should we monitor blood sodium levels if the sweating becomes severe?
- 4.Can you help us connect with a palliative care team now, rather than waiting until the final stages of the disease?
- 5.Are there any active 'expanded access' programs for antisense oligonucleotides (ASOs) or other PrP-lowering therapies that we should be aware of?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (19)
- 1
Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review.
Yang TW, Park B, Kim KT, et al.
Medicine 2018; (97(18)):e0646 doi:10.1097/MD.0000000000010646.
PMID: 29718878 - 2
Agrypnia excitata: a human model to explore the derailment of sleep-wake cycle integrated control.
Mutti C, Baldelli L, Cortelli P, et al.
Journal of sleep research 2025; (34(2)):e14324 doi:10.1111/jsr.14324.
PMID: 39223838 - 3
A case of fatal familial insomnia: diagnostic and therapeutic approaches.
Rose DK, Liu AJ
Neurocase 2022; (28(1)):131-134 doi:10.1080/13554794.2021.2025249.
PMID: 35037601 - 4
From parasomnia to agrypnia excitata - An illustrative case on diagnostic approach.
Fong SL, Dy Closas AMF, Lim TT, et al.
Parkinsonism & related disorders 2023; (109()):105332 doi:10.1016/j.parkreldis.2023.105332.
PMID: 36948111 - 5
A fatal familial insomnia patient newly diagnosed as having depression: A case report.
Yukang T, Jiaquan L, Xiaoling L, et al.
Medicine 2021; (100(41)):e27544 doi:10.1097/MD.0000000000027544.
PMID: 34731156 - 6
[Clinical, neuroimaging and genetic features of two Chinese families with fatal familial insomnia].
Bian Y, Wang S, Han XC, et al.
Zhonghua yi xue za zhi 2018; (98(31)):2501-2504 doi:10.3760/cma.j.issn.0376-2491.2018.31.010.
PMID: 30139003 - 7
Fatal insomnia: the elusive prion disease.
Patel D, Ibrahim H, Rankin J, et al.
BMJ case reports 2021; (14(6)) doi:10.1136/bcr-2020-241289.
PMID: 34158325 - 8
Stridor during sleep: description of 81 consecutive cases diagnosed in a tertiary sleep disorders center.
Silva C, Iranzo A, Maya G, et al.
Sleep 2021; (44(3)) doi:10.1093/sleep/zsaa191.
PMID: 32954431 - 9
[Fatal Familial Insomnia With Significant Correlations Between Involuntary Movements and Postural Changes:Report of One Case].
Zhang L, Sun H, Zhang SM, et al.
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2024; (46(1)):135-138 doi:10.3881/j.issn.1000-503X.15589.
PMID: 38433643 - 10
Sleep architecture and sleep-disordered breathing in fatal insomnia.
Pérez-Carbonell L, Muñoz-Lopetegi A, Sánchez-Valle R, et al.
Sleep medicine 2022; (100()):311-346 doi:10.1016/j.sleep.2022.08.027.
PMID: 36182725 - 11
Dysfunction of the cardiac parasympathetic system in fatal familial insomnia: a heart rate variability study.
Cui Y, Huang Z, Chu M, et al.
Sleep 2023; (46(4)) doi:10.1093/sleep/zsac294.
PMID: 36472576 - 12
Fatal familial insomnia: A new case description with response to thoracic sympathetic nerve thermocoagulation and stellate ganglion block.
Chen Y, Li Y, Zhou Y, et al.
Sleep medicine 2025; (127()):24-27 doi:10.1016/j.sleep.2024.12.034.
PMID: 39765140 - 13
Fatal familial insomnia and Agrypnia Excitata: Autonomic dysfunctions and pathophysiological implications.
Baldelli L, Provini F
Autonomic neuroscience : basic & clinical 2019; (218()):68-86 doi:10.1016/j.autneu.2019.02.007.
PMID: 30890351 - 14
Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice.
Lavigna G, Masone A, Bouybayoune I, et al.
Neurobiology of disease 2021; (158()):105455 doi:10.1016/j.nbd.2021.105455.
PMID: 34358614 - 15
Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases.
Forloni G, Tettamanti M, Lucca U, et al.
Prion 2015; (9(2)):75-9 doi:10.1080/19336896.2015.1027857.
PMID: 25996399 - 16
Antisense oligonucleotides extend survival of prion-infected mice.
Raymond GJ, Zhao HT, Race B, et al.
JCI insight 2019; (5()).
PMID: 31361599 - 17
Genetic aspects of human prion diseases.
Appleby BS, Shetty S, Elkasaby M
Frontiers in neurology 2022; (13()):1003056 doi:10.3389/fneur.2022.1003056.
PMID: 36277922 - 18
[Clinical characteristics and diagnostics of human spongiform encephalopathies: an update].
Hermann P, Goebel S, Zerr I
Der Nervenarzt 2024; (95(4)):376-384 doi:10.1007/s00115-024-01644-2.
PMID: 38503894 - 19
Fatal familial insomnia: Reporting a case of the rare nightmare.
Hogue E, Weinberg D, Palecek E
Journal of postgraduate medicine 2024; (70(4)):252-254 doi:10.4103/jpgm.jpgm_582_24.
PMID: 39660573
This page is for informational purposes only and does not constitute medical advice. Decisions about sedatives, breathing support, electrolyte replacement, and palliative or hospice care should be made with the patient’s neurologist and care team.
Get notified when new evidence is published on Fatal familial insomnia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.